Logo for Pila Pharma

Pila Pharma Investor Relations Material

Latest events

Logo for Pila Pharma

Q4 2023

Pila Pharma
Logo for Pila Pharma

Q4 2023

28 Feb, 2024
Logo for Pila Pharma

Q3 2023

25 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Pila Pharma

Access all reports
PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.